ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Tempest Therpeutics Inc

Tempest Therpeutics Inc (TPST)

3.44
-0.10
(-2.82%)
Closed April 29 4:00PM
3.49
0.05
(1.45%)
After Hours: 7:41PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.49
Bid
3.41
Ask
3.49
Volume
306,788
3.44 Day's Range 3.7164
0.17 52 Week Range 9.77
Market Cap
Previous Close
3.54
Open
3.51
Last Trade
30
@
3.424
Last Trade Time
Financial Volume
$ 1,088,038
VWAP
3.5465
Average Volume (3m)
981,500
Shares Outstanding
19,247,495
Dividend Yield
-
PE Ratio
-2.25
Earnings Per Share (EPS)
-1.53
Revenue
-
Net Profit
-29.49M

About Tempest Therpeutics Inc

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Tempest Therpeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TPST. The last closing price for Tempest Therpeutics was $3.54. Over the last year, Tempest Therpeutics shares have traded in a share price range of $ 0.17 to $ 9.77.

Tempest Therpeutics currently has 19,247,495 shares outstanding. The market capitalization of Tempest Therpeutics is $66.21 million. Tempest Therpeutics has a price to earnings ratio (PE ratio) of -2.25.

TPST Latest News

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Tempest Reports New Preclinical Data for TPST-1120ย in RCC at the AACR Annual Meeting

BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPARโบ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized...

Tempest Reports Year End 2023 Financial Results andย Provides Business Update

Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in...

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest to Present at the 44th Annual TD Cowen Healthcare Conference

BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3912.58064516133.13.71643.084269713.42389536CS
4-0.43-10.96938775513.9263.061117153014.79473004CS
12-0.58-14.25061425064.0763.039815004.37781614CS
26-0.76-17.88235294124.2562.760616779963.8145539CS
521.3160.09174311932.189.770.1731557055.86069529CS
156-10.32-74.728457639413.81410.1712184606.40050943CS
260-10.32-74.728457639413.81410.1712184606.40050943CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSLRComplete Solaria Inc
$ 0.7303
(91.73%)
25.79M
MULNMullen Automotive Inc
$ 5.73
(81.33%)
72.12M
DCPHDeciphera Pharmaceuticals Inc
$ 25.28
(72.56%)
50.72M
CAUDCollective Audience Inc
$ 0.6377
(63.51%)
157.73M
LICNLichen China Limited
$ 2.03
(48.18%)
3.96M
CLVRClever Leaves Holdings Inc
$ 1.62
(-60.58%)
768.37k
ADXNAddex Therapeutics Ltd
$ 7.68
(-52.30%)
160.84k
TSDDGraniteShares ETF Trust GraniteShares
$ 17.1879
(-30.97%)
1.64M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 27.23
(-30.66%)
7.72M
MFImF International Ltd
$ 1.665
(-28.54%)
3.55M
TSLATesla Inc
$ 194.05
(15.31%)
243.77M
SINTSiNtx Technologies Inc
$ 0.053477
(32.37%)
174.36M
CAUDCollective Audience Inc
$ 0.6377
(63.51%)
157.73M
SOFISoFi Technologies Inc
$ 7.045
(-10.48%)
149.62M
SQQQProShares UltraPro Short QQQ
$ 11.31
(-1.05%)
97.67M

TPST Discussion

View Posts
rouge Vaughn rouge Vaughn 4 weeks ago
yup and time to go up even more let's pass 7 and up trmw
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 4 weeks ago
UPstink today
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 month ago
TPST under $4
๐Ÿ‘๏ธ0
retireat40 retireat40 4 months ago
El stinko day today
๐Ÿ‘๏ธ0
BurgerKing82 BurgerKing82 4 months ago
Any other bio cheapies besides hook
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 5 months ago
Was that you 3.12 big
๐Ÿ‘๏ธ0
ORCA ORCA 5 months ago
OUT AT 3.53:))))
๐Ÿ‘๏ธ0
ORCA ORCA 5 months ago
$3.43:))))
๐Ÿ‘๏ธ0
ORCA ORCA 5 months ago
FROM 2.92 MY CALL.NOW 3.38:))))
๐Ÿ‘๏ธ0
ORCA ORCA 5 months ago
AS OF NOW PER SCHWAB IT IS VERY HARD TO FIND SHARES TO SHORT.WELL THAT IS GOING TO BE A B$TCH FOR SHORTS.
๐Ÿ‘๏ธ0
ORCA ORCA 5 months ago
ORCA IS LOOKING TO GET BACK IN AGAIN.THE PPS IS COMING DOWN TO MY ENTERING PRICES:)))
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
This is their reload zone evidently..price going higher
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Under 15min remaining for them to fake-volume trade this..lol
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Price rising with volume
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Wonder which partner Tempest selects for its TPST treatment.
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
โ€œTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)โ€
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
20k share trade at $3.42
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Grabbed $3.50โ€™s..should find out who they partnered with..soon enough
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Grabbed some $3.70โ€™s for next run over $5
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Must be todays conference causing rally
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Up 13%
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Up 12% 2nd million..letโ€™s see 3rd
๐Ÿ‘๏ธ0
tickersym tickersym 5 months ago
Very Nice !!
๐Ÿ‘๏ธ0
tickersym tickersym 5 months ago
Looks ready!!
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Up 7% 1st million volume..letโ€™s see after 2nd
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Yall musta seen 911 trade..bout40min before $3.80โ€™s breakout l..yesterday
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Yall arent very good@what yall do..still got all-my shares
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Yep
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
Bulls taking control premarket evidently
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
16,745 share trade at $3.83
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
โ€œTempest to Present at the 35th Annual Piper Sandler Healthcare Conferenceโ€
๐Ÿ‘๏ธ0
MightyX MightyX 5 months ago
News out or market just happy to see me?
๐Ÿ‘๏ธ0
tickersym tickersym 5 months ago
All Aboard!!!
๐Ÿ‘๏ธ0
bigfart bigfart 6 months ago
$5 would be nice
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
$4โ€™s and $5โ€™s this week?
๐Ÿ‘๏ธ0
TheGreenReaper TheGreenReaper 6 months ago
TPST$$$$$
LETS GET IT.
๐Ÿ‘๏ธ0
tickersym tickersym 6 months ago
Looking great today!!!
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
Yโ€™all arenโ€™t very good at what yโ€™all do lol
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
Yโ€™all gave up too many sharesโ€ฆnow Iโ€™ve got more.
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
Inherent risk in industry..temporary
๐Ÿ‘๏ธ0
ORCA ORCA 6 months ago
THIS POS IS LOSING AN ENORMOUS AMOUNT OF MONEY.IT SHOULD BE TRADING IN THE .30 AREA.MAX.
Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022.
โ€ข
Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.
โ€ข
Research and development expenses for the quarter ended September 30, 2023 were $4.2 million compared to $6.0 million for the same period in 2022. The $1.8 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors.
โ€ข
General and administrative expenses for the quarter ended September 30, 2023 were $2.4 million compared to $2.8 million for the same period in 2022. The decrease was primarily due to a decrease in consulting and professional expenses and personnel costs.


Year-to-Date

โ€ข
Net cash used in operations for the nine months ended September 30, 2023 was $21.2 million.
โ€ข
Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.
Research and development expenses for the nine months ended September 30, 2023 were $13.3 million compared to $16.7 million for the same period in 2022. The $3.4 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors, partially offset by an increase in facilities expenses.
โ€ข
General and administrative expenses for the nine months ended September 30, 2023 were $8.3 million compared to $9.0 million for the same period in 2022. The $0.7 million decrease was primarily due to a decrease in consulting and professional expenses.
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
Nice premarket movement on earnings report..no chart signal lmao.
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
โ€œTempest Reports Third Quarter 2023 Financial Results and Provides Business Updateโ€
๐Ÿ‘๏ธ0
bigboard bigboard 6 months ago
This is scam !! stay away, most phase 2 pumps are scams
They fail in phase 3
๐Ÿ‘๏ธ0
jdes jdes 6 months ago
Yeah but what a pump. From .17 to 9.77 in one day!!! Just had to be lucky that day.
๐Ÿ‘๏ธ0
TheGreenReaper TheGreenReaper 6 months ago
Nope, anytime before the 14th
๐Ÿ‘๏ธ0
bigboard bigboard 6 months ago
On the way to 0.75 !!! This was total pump n dump scam
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
Earnings come out Tuesday?
๐Ÿ‘๏ธ0
TheGreenReaper TheGreenReaper 6 months ago
Waiting on the reversal signal.
๐Ÿ‘๏ธ0
MightyX MightyX 6 months ago
Thatโ€™s just dumb say trader verbiage..no actual knives falling..lol
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock